Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06835569 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Alterome Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 9
- Study locations
NCT06835569 is a Phase 1 study of Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Alterome Therapeutics. The registered enrollment target is 188 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT06835569, a Phase 1 study of Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Alterome Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Conditions Studied
Interventions
- DRUG cetuximab
- DRUG ALTA3263
Study Locations (9)
Texas
- Research Site - Houston
- Research Site #2 - San Antonio
- Research Site - San Antonio
Massachusetts
- Research Site - Boston
- Research Site - Boston
Florida
- Research Site - Orlando
New York
- Research Site - New York
Tennessee
- Research Site - Nashville
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06835569
The ClinicalTrials.gov registry entry for NCT06835569 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Alterome Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which cetuximab is the first listed.
NCT06835569 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Texas, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT06835569 about?
NCT06835569 is a clinical study titled "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations". The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
What is the current status of trial NCT06835569?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2025-03-05. Estimated completion is 2029-08.
What conditions does trial NCT06835569 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, NSCLC (Non-small Cell Lung Cancer), PDAC - Pancreatic Ductal Adenocarcinoma, CRC, Colorectal Cancer.
What interventions are being tested in trial NCT06835569?
The interventions under investigation include: cetuximab (DRUG), ALTA3263 (DRUG).
Who is sponsoring clinical trial NCT06835569?
This trial is sponsored by Alterome Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06835569 being conducted?
This trial has 9 study locations across Florida, Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.